Trial Profile
A Multi-center, Open-label, Uncontrolled, Investigator-initiated Trial to Evaluate the Safety and Efficacy of Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses on the Trunk and Extremities
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis
- Focus Adverse reactions
- Acronyms IMOT001
- 17 Jul 2018 Status changed from recruiting to discontinued.
- 25 Jun 2015 New trial record